Tango Therapeutics, Inc. (TNGX)
NASDAQ: TNGX · Real-Time Price · USD
3.630
-0.450 (-11.03%)
Nov 21, 2024, 4:00 PM EST - Market closed
Tango Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Tango Therapeutics stock have an average target of 13.14, with a low estimate of 8.00 and a high estimate of 19. The average target predicts an increase of 261.98% from the current stock price of 3.63.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for TNGX stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B. Riley Securities | B. Riley Securities | Strong Buy Maintains $16 → $8 | Strong Buy | Maintains | $16 → $8 | +120.39% | Nov 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +258.13% | Nov 8, 2024 |
| Guggenheim | Guggenheim | Strong Buy Maintains $18 → $8 | Strong Buy | Maintains | $18 → $8 | +120.39% | Nov 7, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +258.13% | Oct 28, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +258.13% | Sep 10, 2024 |
Financial Forecast
Revenue This Year
45.86M
from 36.53M
Increased by 25.55%
Revenue Next Year
28.97M
from 45.86M
Decreased by -36.83%
EPS This Year
-1.25
from -1.08
EPS Next Year
-1.48
from -1.25
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 56.3M | 45.6M | 69.1M | ||
| Avg | 45.9M | 29.0M | 30.6M | ||
| Low | 40.5M | 19.6M | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 54.1% | -0.5% | 138.5% | ||
| Avg | 25.6% | -36.8% | 5.7% | ||
| Low | 10.8% | -57.3% | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.17 | -1.27 | -1.08 | ||
| Avg | -1.25 | -1.48 | -1.48 | ||
| Low | -1.29 | -1.58 | -1.61 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.